What Diagnomics does

Diagnomics Inc. operates a CLIA-certified, CAP-accredited, and HIPAA-compliant genomics and liquid biopsy laboratory headquartered at 5050 Murphy Canyon Road in San Diego, California, with affiliated operations in Incheon, South Korea via the KOSDAQ-listed Eone Diagnomics Genome Center (EDGC) joint venture. The company delivers genetic and epigenetic testing services across four primary modalities: next-generation sequencing on Illumina platforms (whole-genome, whole-exome, transcriptome, targeted panels), Illumina microarray-based genotyping and methylation profiling, QuantStudio 12K Flex genotyping, and liquid biopsy covering non-invasive prenatal testing, cancer early detection, and disease monitoring through cfDNA/ctDNA analysis. Its proprietary products include the EpiClock epigenetic biological aging service using MassARRAY iPLEX DNA methylation biomarkers, the AiGenomics AI-powered data analysis platform, and the Diagnomics-On-Cloud bioinformatics platform supporting clinical reporting in regulated CLIA environments; consumer-facing pharmacogenomics (PGx) tests round out the product suite.

The business operates a hybrid B2B/B2C model: enterprise field sales led by a VP of Business Development target global pharmaceutical, biotech, and medical device companies for turnkey clinical research solutions and assay deployment, while hospitals, physicians, and academic institutions consume CLIA/CAP laboratory services; individual consumers purchase tests via the diagnomics.com e-commerce shop. A network of more than 10 channel and reseller partners (including Excellen Medical, Phoenix Lifesciences, Genovive, and others) extends reach into the Mexican and other international markets. Pricing is not publicly disclosed and appears to be quote-based per project or test order, suggesting negotiated contract values rather than standardized SKU pricing. Strategic technology and regulatory partners include Illumina, Intel Health, Advarra IRB, and IntegReview IRB, while founder/CEO Dr. Min Seob Lee concurrently leads EDGC and holds multiple US, Korean, and international patents in personalized medicine and diagnostic development, anchoring the company's research credentials.

Name

Diagnomics

Legal name

Diagnomics Inc.

Website

https://diagnomics.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

1–10 employees

Short description

Diagnomics Inc. is a CLIA-certified, CAP-accredited San Diego genomics and liquid biopsy laboratory offering NGS, microarray, genotyping, epigenetic aging (EpiClock), pharmacogenomics, and AI-driven analytics to pharma, biotech, hospitals, researchers, and consumers globally.

Ownership category

akta.pro rank

Product category

Clinical Genomics Laboratory Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Testing Laboratories (8734), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industries

Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)

Keywords

• Genomic testing services
• Next generation sequencing
• Liquid biopsy analysis
• Pharmacogenomics testing
• Epigenetic aging analysis

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Others

Revenue model

1. Clinical and Consumer Genetic Testing Services: Diagnomics provides genetic testing platform services for both organizations and individual consumers, including liquid biopsy, pharmacogenomics, and epigenetic aging tests. Revenue is generated through direct sales of testing kits and laboratory services to healthcare providers, researchers, and consumers.
2. CLIA/CAP-Certified Laboratory Services: CLIA-certified and CAP-accredited laboratory providing clinical DNA testing, assay deployment, and molecular diagnostics services to pharmaceutical, biotech, medical device companies, hospitals, and physicians. Services include clinical and translational research support and validated testing procedures.
3. Cloud-Based Bioinformatics (Diagnomics-On-Cloud): Cloud-based bioinformatics analysis solutions and clinical reporting delivered through the Diagnomics-On-Cloud platform. Provides data management, bioinformatics pipelines, and IT resources supporting regulated clinical environments.
4. Distribution and Reseller Partnerships: Diagnomics offers distribution partnering and reselling opportunities for genetic testing services to B2B partners including companies, healthcare providers, and organizations seeking to provide DNA-based services to their customers or patients.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Diagnomics Lab is a CLIA-certified, CAP-accredited genomics and liquid biopsy laboratory that delivers NGS-based genetic testing services to pharmaceutical, biotech, medical device, hospital, physician, and academic customers, as well as to individual consumers. Its core sellable offerings include Liquid Biopsy (NIPT, cancer early detection, disease monitoring), the proprietary EpiClock epigenetic aging test, Pharmacogenomics (PGx) testing, and an online Diagnomics Shop for direct-to-consumer purchases, all supported by Illumina-powered NGS, microarray, and QuantStudio genotyping laboratories plus the AiGenomics AI platform and Diagnomics-On-Cloud bioinformatics.

Product overview

Diagnomics Lab operates as a genomics and liquid biopsy laboratory offering precision medicine solutions through an integrated platform architecture. The core offerings include Liquid Biopsy services (encompassing NIPT, cancer early detection, and disease monitoring), the proprietary EpiClock epigenetic aging test, and Pharmacogenomics (PGx) testing. These are supported by three technology platforms: Next Generation Sequencing (NGS) using Illumina technology, Microarray Analysis, and Genotyping Services using QuantStudio. The AI-powered AiGenomics platform provides advanced data analysis and interpretation, while Diagnomics-On-Cloud delivers cloud-based bioinformatics and clinical reporting. Consumers can access services through the Diagnomics Shop.

Differentiator

Problem solved

Functional benefit

Brands

• AiGenomics: Diagnomics' cutting-edge platform that integrates artificial intelligence with genomics to revolutionize data analysis, interpretation, and actionable insights. Designed to deliver high accuracy and scalability, empowering healthcare providers, researchers, and individuals to fully harness genomic data for precision medicine, research, and wellness.
• EpiClock
• Diagnomics-On-Cloud

Products and services

• Liquid Biopsy Non-invasive blood-based analysis platform for detecting genetic and epigenetic biomarkers, supporting non-invasive prenatal testing (NIPT), cancer early detection, and disease monitoring through circulating tumor DNA (ctDNA) profiling. Targeted at healthcare providers, researchers, and individual consumers.
• EpiClock Proprietary epigenetic biological aging analysis service that estimates biological age using DNA methylation biomarkers through MassARRAY iPLEX technology and Diagnomics' proprietary age-associated CpG methylation algorithm. Targeted at consumers and clinicians in longevity and precision medicine programs.
• Pharmacogenomics (PGx) Genetic testing service that analyzes drug metabolism genes to deliver personalized medication and dosage recommendations, covering therapeutic areas including cardiovascular, oncology, psychiatry, pain management, and neurology. Targeted at physicians, healthcare systems, and consumers.
• Next-Generation Sequencing (NGS) Analysis Laboratory Illumina-powered high-throughput sequencing laboratory offering whole-genome sequencing, whole-exome sequencing, transcriptome analysis, and targeted panel sequencing for clinical and research applications. Targeted at pharmaceutical, biotech, medical device, academic, hospital, and physician clients.
• Microarray Analysis Laboratory Illumina microarray-based laboratory service providing genotyping, methylation profiling, and custom array solutions for precision medicine, wellness programs, and population genomics research. Targeted at researchers, clinicians, and industry partners.
• Genotyping Services Laboratory High-throughput genotyping laboratory using the QuantStudio 12K Flex Real-Time PCR System for SNP genotyping, copy number variation analysis, allelic discrimination assays, and custom assay development supporting up to 12,000 data points per run. Targeted at research, clinical, and industrial customers.
• AiGenomics Platform AI-powered genomics data analysis platform integrating artificial intelligence with genomics for precision medicine insights, research support, and wellness optimization using advanced algorithms. Targeted at healthcare providers, researchers, and individuals.
• Diagnomics-On-Cloud Cloud-based bioinformatics platform enabling clinical reporting and molecular assay data management within a CLIA-certified environment for clinical and translational research. Targeted at CLIA/CAP-regulated customers requiring turnkey bioinformatics and clinical reporting.
• Diagnomics Shop Direct-to-consumer online storefront where individual consumers can purchase genetic testing and epigenetic testing services for personalized health insights, processed via PayPal or debit/credit card.

Quantifiable outcome

• Non-invasive prenatal testing with high sensitivity and specificity, reducing need for invasive procedures
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature7 records

Partnerships

16 partnerships are on record, tiered core, major and minor.

• Eone Diagnomics Genome Center (EDGC)coreStrategic or Co-development PartnerKorean joint venture between Diagnomics and Eone Diagnostics, listed on KOSDAQ (EDGC). Dr. Min Seob Lee serves as CEO of EDGC. The partnership enables international expansion of genomics services, combining Diagnomics' technology platforms with EDGC's Korean market presence. EDGC video content is featured on Diagnomics' website.
• IlluminacoreTechnology or IntegrationDiagnomics uses Illumina sequencing technology platforms for its NGS laboratory, including systems for whole-genome sequencing, whole-exome sequencing, and transcriptome analysis. Also utilizes Illumina microarray platforms. Dr. Lee was featured in an Illumina interview. Illumina is a featured partner on Diagnomics' website.
• Advarra IRBcoreTechnology or IntegrationDiagnomics utilizes the Advarra IRB framework and CIRBI electronic research management platform for ethical review, regulatory oversight, and administration of human subject research. Advarra provides independent IRB services ensuring compliance with applicable regulatory and ethical standards for genomics research.
• IntelmajorTechnology or IntegrationStrategic partnership with Intel Health focused on computing infrastructure for precision medicine. Intel contributed to Diagnomics' genomic data processing capabilities. An Intel white paper features Diagnomics as a case study for Intel Xeon Processor applications in genome analysis. Michael O'Reilly (VP of Business Development) facilitated the Intel Health partnership.
• Excellen MedicalminorChannel Partner/ Reseller/ DistributorListed as a Diagnomics partner on the company website. Partnership appears to involve distribution of genetic testing services or co-marketing of genomics solutions to healthcare providers and patients.
• Phoenix LifesciencesminorChannel Partner/ Reseller/ DistributorListed as a Diagnomics partner on the company website. Partnership enables expansion of genomics services and liquid biopsy solutions to Phoenix Lifesciences' network of customers.
• Genomics Personalized HealthminorChannel Partner/ Reseller/ DistributorListed as a Diagnomics partner. Focuses on personalized health applications of genetic testing and precision medicine services.
• GenomecareminorChannel Partner/ Reseller/ DistributorListed as a Diagnomics partner. Provides genomics services to customers or patients in healthcare settings.
• Accugene LabminorChannel Partner/ Reseller/ DistributorListed as a Diagnomics partner. Serves as a genetic testing distribution partner for genomics services.
• ResearchDxminorChannel Partner/ Reseller/ DistributorListed as a Diagnomics partner specializing in diagnostic research and development. Partnership supports clinical research and molecular assay development.
• Comp Pro MedminorChannel Partner/ Reseller/ DistributorListed as a Diagnomics partner. Medical diagnostics distribution partner.
• GenoviveminorChannel Partner/ Reseller/ DistributorListed as a Diagnomics partner. Serves the Mexican market for genomics and personalized health services.
• NGENI FoundationminorStrategic or Co-development PartnerNGENI Foundation (California-based) promotes research in precision medicine and scientific discoveries from genomics and health data. Dr. Min Seob Lee serves as a director of NGENI Foundation.
• AigenomicsminorChannel Partner/ Reseller/ DistributorListed as a Diagnomics partner on the company website. Aigenomics appears to be related to AI-driven genomics solutions.
• EDGC (Eone Diagnostics Genome Center)minorChannel Partner/ Reseller/ DistributorListed as a Diagnomics partner on the company website alongside the EDGC video showcasing genomics services as a first genomics partner.
• AiGenomicsmajorStrategic or Co-development PartnerAiGenomics is Diagnomics' own cutting-edge platform that integrates artificial intelligence with genomics. It is presented as a fusion of AI and genomics designed to deliver high accuracy and scalability for precision medicine, research, and wellness applications. This is an internal platform developed by Diagnomics to power its service offerings.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Guardant Health: Liquid biopsy leader in ctDNA-based oncology testing (G360, Shield, Reveal). Direct overlap with Diagnomics' liquid biopsy / early cancer detection product line and similar NGS-based diagnostic regulatory pathway.
• Helix: NGS-based population genomics platform partnering with health systems and biopharma on clinical-grade genomic testing. Comparable in NGS platform economics, CLIA operations, and biopharma partnership model.
• Sema4: Genomics-driven precision medicine company offering diagnostic NGS, reproductive health, and oncology testing to providers and pharma. Comparable in NGS clinical reporting and pharma translational research offerings.
• Color: Genetic testing company operating across DTC and B2B (employers, providers, health systems) with CLIA-validated NGS workflows. Closely comparable in DTC genetic testing, clinical reporting, and B2B2C distribution model.
• Natera: NGS-based molecular diagnostics across reproductive health (NIPT), oncology (Signatera), and organ transplant. Comparable in NGS workflow and clinical-reporting model to Diagnomics, including NIPT and oncology liquid biopsy offerings.
• Personalis: NGS-based genomics lab specializing in immuno-oncology and whole-genome sequencing for pharma/biopharma clinical research. Comparable in NGS-driven translational services and pharma/biotech customer base.
• Tempus: AI-enabled precision medicine lab offering NGS-based molecular profiling and clinical reporting to pharma, providers, and patients. Closely comparable to Diagnomics in the AI-on-genomics wedge, but at substantially greater scale.

Broad incumbents

• Foundation Medicine: Molecular diagnostics company (now part of Roche) offering comprehensive genomic profiling for oncology. Comparable NGS-based diagnostic workflow and pharma/biotech CDx development model.
• Exact Sciences: Molecular diagnostics company spanning Cologuard and Oncotype DX with growing precision oncology and PGx portfolios. Comparable in molecular diagnostics positioning and screening/monitoring use cases relevant to Diagnomics' liquid biopsy roadmap.
• NeoGenomics: Established clinical oncology and molecular diagnostics lab with broad NGS, IHC, and cytogenetics menu serving hospitals and oncologists. Comparable clinical lab offerings and regulatory footprint, but at much broader scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Diagnomics